Deltagen Inc represents values of innovation, collaboration, and customer-centricity. With a strong corporate philosophy, the company focuses on advancing scientific research and biotechnological solutions. Deltagen Inc aims to improve the quality of life by delivering cutting-edge products and services in the field of genetic engineering. The company prioritizes ethical practices, emphasizes scientific integrity, and values transparency in its operations. With a commitment to excellence and a passion for making a difference, Deltagen Inc strives to be a leader in the biotechnology industry, continually seeking new opportunities for growth and advancements in the field.

Deltagen Inc primarily operates in the United States.

Deltagen Inc, a renowned company in the stock market, has accomplished several remarkable milestones. Since its establishment, Deltagen Inc has successfully positioned itself as a leading player in its industry. The company's notable achievements include significant financial growth, forging strategic partnerships with major market players, and developing innovative solutions that have disrupted the market. Deltagen Inc has consistently delivered exceptional results, securing a prominent position among competitors. Through its commitment to excellence and consistent efforts, Deltagen Inc has carved a remarkable path, establishing itself as a trusted and influential force in the stock market.

Deltagen Inc is a renowned company with a rich history and background. Founded in [year], Deltagen Inc has established itself as a leader in [industry/sector]. The company focuses on [brief description of main activities/products/solutions]. Over the years, Deltagen Inc has successfully [accomplishments/achievements]. With a strong presence in the market, this company continues to [key activities that contribute to success]. Deltagen Inc's commitment to innovation and quality has earned them a solid reputation among [industry/sector] professionals and investors alike. Through their exceptional expertise and dedication, Deltagen Inc remains a prominent player in the [industry/sector], continually striving for excellence.

The main competitors of Deltagen Inc in the market include other companies in the biotechnology sector such as Genentech, Amgen, and Novartis. These companies also focus on developing and marketing innovative drugs and therapies, making them direct competitors to Deltagen Inc. With its unique portfolio and cutting-edge research, Deltagen Inc strives to differentiate itself in the market and maintain a competitive edge against these industry rivals.

Deltagen Inc is primarily active in the field of biotechnology and pharmaceuticals.

Deltagen Inc. operates under the business model of a biotechnology company. The company specializes in the discovery and development of innovative therapeutics using gene targeting and knockout technologies. Through its advanced research and development processes, Deltagen Inc. aims to identify and validate potential drug targets and pathways, leading to the creation of novel therapies for various diseases and medical conditions. With its emphasis on genetic research and cutting-edge technologies, Deltagen Inc. strives to make significant contributions to the healthcare industry by advancing the understanding and treatment of complex human diseases.

De K/W-verhouding kan momenteel niet worden berekend voor Deltagen.

De KUV kan momenteel niet worden berekend voor Deltagen.

De AlleAktien Kwaliteitsscore voor Deltagen is 2/10.

De omzet kan momenteel niet worden berekend voor Deltagen.

De winst kan momenteel niet berekend worden voor Deltagen.

The company Deltagen Inc is a research and development company based in San Diego, California, specializing in the fields of biotechnology, pharmacology, and life sciences. Its business model includes several interconnected divisions. One of the leading divisions of Deltagen Inc is pharmacological research, where the company develops and tests innovative drugs to combat diseases and improve health. It utilizes advanced technologies such as CRISPR-Cas9 gene editing, leading to the development of new biotechnologies. Another division of Deltagen Inc is molecular diagnostics, which aims to early detect and treat diseases. The division employs cutting-edge technologies such as Next-Generation Sequencing, accelerating genomic and proteomic research, as well as artificial intelligence for the analysis of medical images. Deltagen Inc is also a leading provider of bioinformatics software, allowing customers to analyze and evaluate their own research data. The software is tailored to the needs of biotechnology and pharmaceutical companies, facilitating their involvement in drug and product development. Furthermore, Deltagen Inc is involved in platform technology and utilizes its expertise to develop a variety of applications. One of the current platform technologies under development is the DSP (Drug Screen Platform) for drug discovery. However, Deltagen Inc not only offers research and development services but also has a range of products. These include genetically modified animal models that can be used for disease research and drug development. Overall, Deltagen Inc benefits from this integrated business model, setting it apart from other companies that focus on a specific discipline. The combination of research and development of new products creates a unique value, enabling the company to grow in research and development through innovation.

Deltagen keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Deltagen of het bedrijf keert geen dividend uit.

De ISIN van Deltagen is US24783R1032.

Het WKN van Deltagen is 938999.

De ticker van Deltagen is DGEN.

Binnen de laatste 12 maanden betaalde Deltagen een dividend van 0,20 USD . Dit komt overeen met een dividendrendement van ongeveer 20,00 mln. %. Voor de komende 12 maanden zal Deltagen naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Deltagen is momenteel 20,00 mln. %.

Deltagen betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Deltagen betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Deltagen wordt toegewezen aan de sector '—'.

Om het laatste dividend van Deltagen van 31-5-2007 ter hoogte van 0,05 USD te ontvangen, moest je het aandeel voor de ex-datum op 17-5-2007 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 31-5-2007.

In het jaar 2023 heeft Deltagen 0 USD aan dividenden uitgekeerd.

De dividenden van Deltagen worden in USD uitgekeerd.